Suppliers and packagers for generic pharmaceutical drug: Tofersen

Tofersen

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887	NDA	Biogen Inc.	64406-109-01	1 VIAL, SINGLE-USE in 1 CARTON (64406-109-01) / 15 mL in 1 VIAL, SINGLE-USE	2023-04-25

Suppliers for Tofersen (Spinraza; Biohaven Biopharma) in the US: Drug Substance, Drug Product, and Clinical-Stage Sources

Last updated: May 26, 2026

Tofersen (Spinraza; intrathecal antisense oligonucleotide) supply is concentrated around a small set of specialized manufacturers with oligonucleotide drug substance capability and sterile intrathecal fill-finish capability. Commercial US supply is anchored by the company responsible for marketing Spinraza and its contract partners for active ingredient and finished dosage form.

Who supplies tofersen drug substance and finished product?

Tofersen is manufactured as an antisense oligonucleotide (ASO) for intrathecal delivery. The supply chain typically splits into (1) drug substance (oligonucleotide synthesis, purification, characterization, release testing) and (2) drug product (sterile manufacturing, intrathecal filling, packaging, labeling, and cold-chain logistics where required).

Typical supplier roles

• Drug substance (DS) manufacturers: produce and release the synthesized oligonucleotide under GMP.
• Drug product (DP) manufacturers: perform sterile fill-finish and packaging for intrathecal administration.
• Testing/release labs: conduct analytical methods and lot release support.
• Logistics/wholesaler distribution: manage controlled-temperature distribution and inventory.

Direct supplier mapping requires Orange Book-style listings or CMC/registration disclosures. Without those specific reference documents for each supplier contract, the only defensible “supplier” statements are role-based.

What contract manufacturers make tofersen (Spinraza) for Biohaven?

The practical answer for “who makes it” in the US market is that Biohaven Biopharma (Spinraza marketer in the US) sources drug substance and drug product through contract manufacturing organizations specialized in oligonucleotides and sterile sterile fill-finish.

Key CMC bottlenecks for tofersen supply

• Oligonucleotide synthesis and purification at GMP scale (sequence-specific process control).
• Sterile manufacturing and intrathecal fill-finish (aseptic processing controls).
• Analytical release testing for ASO identity, purity, and potency.
• Stability and cold-chain handling through distribution.

Which suppliers support the intrathecal sterile fill-finish for tofersen?

Intrathecal ASO products require sterile, controlled aseptic fill-finish with containment and validated cleaning to prevent cross-contamination. The finished dose must meet sterility assurance, particulate limits, and container-closure integrity. These tasks are generally performed by contract aseptic fill-finish providers with experience in oncology and CNS biologics/oligonucleotides and validated sterile manufacturing systems.

Are there alternative tofersen suppliers for generic or biosimilar entry?

Tofersen is an antisense oligonucleotide, not a conventional small molecule and not a biologic under the BPCIA pathway. The “generic supplier” concept for ASOs is still constrained by:

• sequence-specific manufacturing controls,
• batch-to-batch comparability for oligonucleotide chemistry,
• rigorous CMC requirements under ANDA-style or 505(b)(2) regulatory frameworks for complex generics, depending on labeling and reference reliance.

Commercially, there is no approved “generic tofersen” supplier substitute in the US market at launch-level scale.

What sourcing risks exist for tofersen supply?

Supply risk drivers for oligonucleotide CNS products

• DS manufacturing capacity is sequence-specific and tightly process-controlled.
• Analytical testing bandwidth can constrain lot release.
• Sterile fill-finish capacity is shared across multiple sterile products, with capacity bottlenecks during maintenance or contamination events.
• Cold-chain distribution adds logistics and temperature monitoring overhead.

What manufacturers supply tofersen outside the US?

Outside the US, supply is generally regionally managed through:

• local marketing authorization holders,
• regional wholesalers,
• local or regional contract fill-finish sites when regulatory filings require it.

In practice, the “active” supplier set can change per region because label, container configuration, and packaging requirements differ.

How to identify the real tofersen suppliers used in US commercial supply?

The most reliable ways to identify the named manufacturing suppliers used for US commercial supply are:

• FDA Drug Product and Drug Substance manufacturing site disclosures in application materials and labeling/CMC sections.
• Inspection and establishment datasets (FDA inspection reports and establishment registrations) that map drug product manufacturing to named sites.
• Lot release and testing site information in manufacturing controls filings.

Without those specific dossier references tied to named establishments and contract manufacturers, any attempt to list suppliers by name risks factual error.

Key takeaways

• Tofersen supply is dominated by specialized ASO drug substance manufacturing and sterile intrathecal fill-finish capacity.
• Contract manufacturing for oligonucleotide DS and sterile DP is the core supplier model for Spinraza in the US.
• Public, investor-grade supplier identification requires FDA establishment-level and CMC-linked disclosures; role-based mapping is the only fully defensible level without dossier-linked supplier names.

FAQs

1. How are tofersen supply contracts typically structured for drug substance vs drug product?
   DS is sourced from oligonucleotide-capable GMP manufacturers; DP is sourced from sterile fill-finish contract manufacturers under validated aseptic processing.

2. What manufacturing capabilities are required to supply tofersen?
   GMP oligonucleotide synthesis and purification for DS, plus sterile intrathecal fill-finish with validated aseptic controls for DP.

3. Do tofersen suppliers differ by country or marketing authorization holder?
   Yes, regional packaging and regulatory requirements can shift which DP sites are used, even if DS remains centralized.

4. What is the biggest supply bottleneck for intrathecal antisense oligonucleotides like tofersen?
   Sterile fill-finish capacity and lot-release analytical throughput are common constraints.

5. Can other companies supply “generic tofersen” for the US market?
   No approved generic tofersen supply substitute is established in the US market at the level of commercial availability; entry would require complex ASO CMC and regulatory pathways.

---

References (APA)

1. FDA. (n.d.). Drug establishment registration and drug listing. U.S. Food and Drug Administration.
2. FDA. (n.d.). Biosimilar and generic drug information resources. U.S. Food and Drug Administration.
3. EMA. (n.d.). European public assessment reports (EPAR) and product manufacturing details. European Medicines Agency.